Uther Peptide Advances Structure-Defined Adalank R&D Program with Adamantane-Modified Research Sequence
The company establishes a defined molecular specification and analytical development pathway for
TR
By Tom Reyes · Markets Editor
Nov 4 04:00 ETSource: Cantech Letter
From the source
Read at cantechletter.comUther Peptide Advances Structure-Defined Adalank R&D Program with Adamantane-Modified Research Sequence
The company establishes a defined molecular specification and analytical development pathway for Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-Adam-NH.
